Deepak Vadhan, MD
Sleep Medicine · Brooklyn, NYNPI 1245314954
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 479 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 30.8% of the total.
Across 479 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$1K
- Regeneron Healthcare Solutions, Inc.$697
- Lilly USA, LLC$565
- Insmed, Inc.$436
- plus $2K from 19 others
What the payments were for
- Food & beverage$10,08796%
- Education$4734%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 158 | $3,250 |
| GSK | 103 | $1,957 |
| Boehringer Ingelheim | 59 | $1,283 |
| Regeneron Healthcare Solutions, Inc. | 25 | $697 |
| Lilly USA, LLC | 25 | $565 |
| Insmed, Inc. | 12 | $436 |
| Electromed, Inc. | 14 | $367 |
| Mallinckrodt Enterprises LLC | 6 | $339 |
| Amgen | 17 | $333 |
| Actelion Pharmaceuticals US, Inc. | 10 | $248 |
| Advanced Respiratory, Inc | 9 | $232 |
| Sanofi | 7 | $179 |
| Philips North America LLC | 5 | $122 |
| Paratek Pharmaceuticals, Inc. | 6 | $97 |
| Mallinckrodt Hospital Products Inc. | 3 | $91 |
| Mylan Specialty L.p. | 5 | $88 |
| Verona Pharma, Inc. | 2 | $52 |
| Genentech USA, Inc. | 3 | $50 |
| Novo Nordisk | 3 | $46 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Merck | 2 | $29 |
| Intra-sana Laboratories | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Baxter Healthcare | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$232
How this compares
$10,560 in reported general payments places this provider in the 80th percentile of 81 sleep medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 235 | $256,574 |
| OfevNintedanib Esylate | 20 | $242,111 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 147 | $147,647 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 139 | $133,875 |
| NucalaMepolizumab | 27 | $100,117 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $51,395 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 72 | $49,358 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $43,897 |
| Spiriva RespimatTiotropium Bromide | 23 | $29,712 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $26,550 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $13,434 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 198 | $8,423 |
| AirsupraAlbuterol Sulfate/Budesonide | 14 | $7,203 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $4,710 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,957 | $342,718308 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,283 | $321,181115 claims |
| Lilly USA, LLCMounjaro | $565 | $256,574235 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $3,250 | $181,399223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 81 sleep medicine providers in New York.
Other sleep medicine in Brooklyn
- Jeremy WeingartenBrooklyn$1K
- Jeanne DamianBrooklyn$338
- Irina PetrenkoBrooklyn$329
- David RapoportNew York$313K
- Ofer JacobowitzNew York$141K
- Qanta AhmedMineola$83K
- Andrew WestwoodNew York$82K
- Omar BurschtinNew York$71K
- Maha AhmadNew York$38K
- Daniel BaroneNew York$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.